Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
WD repeat domain 55 (WDR55)
- Target
- WDR55
- Molecular classification
- WD repeat domain-containing protein, Nucleolar protein, Scaffold/adaptor protein (within E3 ubiquitin ligase complexes in plants/animals)
01
Overview
WD repeat domain 55 (WDR55) is a nucleolar WD repeat-containing protein that modulates rRNA synthesis and is essential for cellular and organismal development. It contains seven WD repeats and localizes to both the nucleus and cytoplasm. WDR55 participates in the assembly or function of CUL4-DDB1 ubiquitin E3 ligase complexes, acting as a substrate recruiter in plants and possibly in animals. Loss-of-function mutations in WDR55 lead to embryonic death and defects in gametogenesis and organ development in model organisms. While the broader WD repeat family is associated with functions such as signal transduction, cell cycle regulation, and apoptosis, WDR55's specific role centers on rRNA processing, cell cycle progression, and development. Currently, WDR55 is not a known therapeutic target or biomarker in clinical practice[1][2][3][4][5].
- Other names
- WD repeat-containing protein 55FLJ20195FLJ21702WDR55
02
Mechanism of action
Not applicable (no therapeutic drugs targeting WDR55 are known)
03
Biological functions
Modulator of rRNA synthesisRegulation of cell cycle progressionOrganogenesis and embryonic developmentGametogenesis (in plants and model organisms)
04
Disease associations
Embryonic lethality and developmental defects (observed in knockout animal models; not directly linked to human disease but essential for viability and organ development)Possible association with regulation of cell proliferation (the WD repeat family in general is linked to cancer, apoptosis, etc., but specific clinical links for WDR55 in humans are not reported)
05
Safety considerations
None reported (as a non-therapeutic target, WDR55 does not have drug-related safety concerns; genetic knockout in animals results in severe developmental/embryonic defects)
06
Interacting drugs
None reported (no drugs known to interact directly with WDR55 based on available data)
07
Biomarkers
None reported (WDR55 is not currently used as a biomarker for patient selection or efficacy monitoring)
Beyond the preview
Go deeper on WD repeat domain 55 (WDR55).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WD repeat domain 55 (WDR55).